secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001493152-24-009766
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus reports FY2023 loss of $1.83/sh; cash $13.4M; Phase 1 Decoy20 advancing
--------------------------------------------------------------------------------

- FY2023 net loss per share $1.83 vs $1.73 in FY2022; cash at Dec 31, 2023 was $13.4M (down from $26.4M).
- Cash runway expected through Q3 2024; excludes $0.3M ATM proceeds in March 2024.
- Positive results from second cohort of Phase 1 Decoy20 trial; initiating multi-dose in solid tumors.
- European patent approved in Jan 2024 for platform technology covering viral infection composition.
- R&D expenses rose 21% YoY to $7.6M driven by Phase 1 trial and pipeline expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315224009766/0001493152-24-009766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315224009766/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-009766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer